<DOC>
	<DOCNO>NCT02043821</DOCNO>
	<brief_summary>Colorectal cancer patient metastasis ( mCRC ) response first-line chemotherapy candidate convenient maintenance treatment .</brief_summary>
	<brief_title>Maintenance Chemotherapy Metastatic Colorectal Carcinoma Biological Marker</brief_title>
	<detailed_description>Colorectal cancer one common malignant tumor , morbidity approximate 100 million case per year . About 40 % patient present metastatic ( stage IV ) colorectal cancer time diagnosis , 25 % patient local lesion ultimately develop metastatic disease.Therefore , study design investigate colorectal cancer patient metastasis ( mCRC ) response first-line chemotherapy candidate convenient maintenance treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Age 18 75 year Eastern Cooperative Oncology Group performance status ( ECOG PS ) 01 histologically confirm colorectal cancer inoperable locally advanced recurrent and/or metastatic disease Life expectancy least 3 month Intact organ function , include complete blood count ( CBC ) show normal value toxicity limit grade 1 blood chemistry ( SMA ) show liver renal function &lt; 1.5 upper normal limit ( UNL ) . Patients achieve objective response stable disease 1624 week first line chemotherapy Signed informed consent Known hypersensitivity capecitabine Concurrent cancer ( except BCC squamous cell carcinoma skin ) . Inability adhere monthly visit oncology unit evaluation . Presence brain metastasis . Previous radiotherapy site measurable disease . Evidence severe uncontrolled systemic disease No previous chemotherapy metastatic disease Positive serum pregnancy test woman childbearing potential unresolved bowel obstruction malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>